• Title of article

    First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons

  • Author/Authors

    Rudi Coninx، نويسنده , , C Mathieu، نويسنده , , M Debacker، نويسنده , , R. S. Mirzoev and Yu. S. Lipatov ، نويسنده , , A Ismaelov، نويسنده , , R de Haller، نويسنده , , DR Meddings، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1999
  • Pages
    5
  • From page
    969
  • To page
    973
  • Abstract
    Background We assessed a programme of tuberculosis control in a prison setting in Baku, Azerbaijan. The programme used first-line therapy and DOTS (directly observed treatment, short course). Methods 467 patients had sputum-positive tuberculosis. Their treatment regimens followed WHO guidelines, and they had regular clinical examinations and dietary supplements. Isolates were tested by standard methods for resistance to isoniazid, rifampicin, ethambutol, and streptomycin in three laboratories. Treatment success was defined as three consecutive negative sputum smears at end of treatment. Factors independently associated with treatment failure were estimated by logistic regression. Findings Drug-resistance data on admission were available for 131 patients. 55% of patients had strains of Mycobacterium tuberculosisresistant to two or more antibiotics. Mortality during treatment was 11%, and 13% of patients defaulted. Overall, treatment was successful in 54% of patients, and in 71% of those completing treatment. 104 patients completed a full treatment regimen and remained sputum-positive. Resistance to two or more antibiotics, a positive sputum result at the end of initial treatment, cavitary disease, and poor compliance were independently associated with treatment failure. Interpretation The effectiveness of a DOTS programme with first-line therapy fell short of the 85% target set by WHO. First-line therapy may not be sufficient in settings with a high degree of resistance to antibiotics.
  • Journal title
    The Lancet
  • Serial Year
    1999
  • Journal title
    The Lancet
  • Record number

    579868